New AML Treatment: Four-Drug Combination Study
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of four medications (chidamide, venetoclax, azacitidine, and homoharringtonine) for newly diagnosed acute myeloid leukemia (AML) in younger, healthier patients. The goal is to see if this combination can help control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed AML (blood cancer) and have not received any AML treatment yet
- You are between 18 and 60 years old
- Your kidneys work reasonably well (creatinine clearance ≥30 mL/min)
- Your liver function is acceptable (ALT less than 5× normal, bilirubin less than 3× normal)
- You are healthy enough to handle intensive treatment (ECOG performance status ≤3)
- You can take pills by mouth and are not allergic to the study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent, as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works well and is safe.
This trial tests whether a new combination (DEC3-VEN) works better than two other standard treatments for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find the best initial therapy to help achieve remission.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
This study tests a combination of four drugs (venetoclax, homoharringtonine, azacitidine, and G-CSF) for people with newly diagnosed AML who cannot tolerate standard intensive chemotherapy. The goal is to see if this lower-intensity therapy can effectively treat the leukemia with fewer side effects.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.